10-Q · May 14, 2026
Oncolytics Biotech's Q1 2026 report highlights a significant increase in operating losses alongside a jump in research and development expenses. The company's cash position improved slightly, but ongoing operational…
Earnings analysis · 10-Q
ONCY earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt contains no income statement, balance sheet, cash flow, segment, or quantitative outlook data, so revenue, margins, EPS, liquidity and free cash flow trends cannot be assessed. Management…
Read full summary
The provided 10-Q excerpt contains no income statement, balance sheet, cash flow, segment, or quantitative outlook data, so revenue, margins, EPS, liquidity and free cash flow trends cannot be assessed. Management reported effective disclosure controls as of June 30, 2026 and no material changes to internal controls during the quarter. The company also reported no material changes to its risk factors from the December 31, 2025 Form 10-K.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was recorded, processed, summarized and reported timely.
-
No material control changes
The company reported no change during the three months ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
-
No material legal proceedings
The company stated it was not currently party to any material legal proceedings or claims outside the ordinary course of business.
What to watch
-
No updated risk-factor disclosure
The filing states there have been no material changes to the risk factors disclosed in the December 31, 2025 Form 10-K, so no new or updated risk disclosures were provided for the quarter ended June 30, 2026.
Management's outlook
No quantitative revenue or EPS outlook was disclosed in the provided filing text; forward guidance was not provided.
Earlier filings 2
10-K · March 30, 2026
Oncolytics Biotech is a clinical-stage company developing pelareorep as an intravenous oncolytic/immunotherapy and is positioning it as a platform for gastrointestinal cancers with planned registrational opportunities…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.